(CercleFinance.com) – While lowering its price target from 127 to 120 euros, Invest Securities reiterates its ‘buy’ opinion on bioMérieux, ‘an unfairly discounted stock in the IVD (in vitro diagnostics) industry given its remarkable ability to navigate the Post-Covid era.
The 2024 PER for the next financial year is around 23 times with a yield close to 1%.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
